Physician profile
Beth L Oller
NPI 1629236393
$570.52
in general payments reported to CMS, 2019-2025
15 companies · $49.07 in 2025
The $49.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.05 · 2020: $130 · 2021: $153 · 2022: $89.58 · 2023: $16.54 · 2024: $64.79 · 2025: $49.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $175.63 | 2019-2021 | |
| Abbvie INC. | $66.52 | 2021-2024 | |
| Medtronic, INC. | $49.07 | 2025 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $46.58 | 2019-2021 | |
| Insulet Corporation | $46.15 | 2024 | Omnipod |
| Amgen INC. | $40.70 | 2019-2022 | |
| Boston Scientific Corporation | $23.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.30 | 2022 | |
| Dexcom, INC. | $17.44 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.54 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2020 | |
| Lilly USA, LLC | $14.16 | 2022 | |
| Daiichi Sankyo INC. | $13.54 | 2021 | |
| Novo Nordisk INC | $12.65 | 2019 | |
| Abbott Laboratories | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Oller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.